Brief: Aptose Reports Results For The First Quarter 2023
08/05/2023 22:20
May 8 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE REPORTS RESULTS FOR THE FIRST QUARTER 2023
* QTRLY LOSS PER SHARE $0.15
* APTOSE BIOSCIENCES - DOUBLET OF TUSPETINIB AND VENETOCLAX
DOSING
UNDERWAY FOR RELAPSED/REFRACTORYAML PATIENTS IN
APTIVATEEXPANSIONTRIAL
* Q1 EARNINGS PER SHARE VIEW $-0.12 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX1S6P6x
Further company coverage: APS.TO
((Reutersbriefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting